CY1106385T1 - Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου - Google Patents

Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου

Info

Publication number
CY1106385T1
CY1106385T1 CY20071100363T CY071100363T CY1106385T1 CY 1106385 T1 CY1106385 T1 CY 1106385T1 CY 20071100363 T CY20071100363 T CY 20071100363T CY 071100363 T CY071100363 T CY 071100363T CY 1106385 T1 CY1106385 T1 CY 1106385T1
Authority
CY
Cyprus
Prior art keywords
subparathyroidism
treatment
epothilone derivatives
epothilone
animal
Prior art date
Application number
CY20071100363T
Other languages
Greek (el)
English (en)
Inventor
Eugene A. Woltering
Original Assignee
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College filed Critical Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
Publication of CY1106385T1 publication Critical patent/CY1106385T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20071100363T 2002-10-15 2007-03-15 Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου CY1106385T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
PCT/IB2003/004514 WO2004035050A1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism

Publications (1)

Publication Number Publication Date
CY1106385T1 true CY1106385T1 (el) 2011-10-12

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100363T CY1106385T1 (el) 2002-10-15 2007-03-15 Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου

Country Status (15)

Country Link
US (2) US20060142354A1 (cg-RX-API-DMAC10.html)
EP (1) EP1553938B1 (cg-RX-API-DMAC10.html)
JP (1) JP4672368B2 (cg-RX-API-DMAC10.html)
CN (1) CN1297269C (cg-RX-API-DMAC10.html)
AT (1) ATE350034T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003267751A1 (cg-RX-API-DMAC10.html)
BR (1) BR0315293A (cg-RX-API-DMAC10.html)
CA (1) CA2501717C (cg-RX-API-DMAC10.html)
CY (1) CY1106385T1 (cg-RX-API-DMAC10.html)
DE (1) DE60310975T2 (cg-RX-API-DMAC10.html)
DK (1) DK1553938T3 (cg-RX-API-DMAC10.html)
ES (1) ES2279139T3 (cg-RX-API-DMAC10.html)
PT (1) PT1553938E (cg-RX-API-DMAC10.html)
SI (1) SI1553938T1 (cg-RX-API-DMAC10.html)
WO (1) WO2004035050A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69403966T3 (de) * 1993-07-19 2008-04-17 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene mittel und verfahren zu deren verwendung
ATE267197T1 (de) * 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
KR20080016756A (ko) * 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Also Published As

Publication number Publication date
DE60310975D1 (de) 2007-02-15
SI1553938T1 (sl) 2007-06-30
JP2006504751A (ja) 2006-02-09
JP4672368B2 (ja) 2011-04-20
BR0315293A (pt) 2005-08-30
US20060142354A1 (en) 2006-06-29
WO2004035050A1 (en) 2004-04-29
CN1297269C (zh) 2007-01-31
US20110152329A1 (en) 2011-06-23
ATE350034T1 (de) 2007-01-15
PT1553938E (pt) 2007-03-30
EP1553938A1 (en) 2005-07-20
DK1553938T3 (da) 2007-03-26
EP1553938B1 (en) 2007-01-03
ES2279139T3 (es) 2007-08-16
AU2003267751A1 (en) 2004-05-04
CN1703217A (zh) 2005-11-30
CA2501717A1 (en) 2004-04-29
HK1080768A1 (en) 2006-05-04
DE60310975T2 (de) 2007-07-12
CA2501717C (en) 2012-09-18

Similar Documents

Publication Publication Date Title
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
CY1106283T1 (el) Κινολινυλ-πυρρολοπυραζολες
CY1113766T1 (el) Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
NO20052512L (no) Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
BRPI0413152A (pt) derivados de benzimidazol alquilado por n3 como inibidores de mek
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
ATE440603T1 (de) 8-hydroxychinolinderivate
CY1105603T1 (el) Συνεργιστικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της ρενινης, για καρδιαγγειακες νοσους
CY1112232T1 (el) Κινολινικα παραγωγα ως αναστολεις φωσφοδιεστερασης
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
ATE384058T1 (de) Thiazolderivate
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
CY1117504T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
NO20052908D0 (no) Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
EA200601249A1 (ru) Пиперазины, пригодные для лечения боли
CY1105591T1 (el) Αναστολεις για συνθαση του 20-ηετε
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων